rubella
RUBELLA
Rubella, also known as German measles or 3-day measles, is a mild often exanthematous disease of infants and children that is severe and associated with complications in adults. It is self-limiting disease associated with a characteristic maculopapular rash.
It is caused by a single-stranded RNA virus classified as a togavirus, genus Rubivirus.
Transmission is through airborne or droplets shed from respiratory secretions.
Highly communicable at the onset of the rash, however viral shedding may also occur 5-7 days before, to 5-7 days or more following appearance of the rash.
The incubation period is 14-21 days.

Prevention

Rubella vaccine is available as a single-antigen preparation or combined w/ other vaccines [eg mumps & rubella (MMR), or also w/ varicella (MMRV)]

  • MMRV is approved for use in healthy children ≥1-12 yrs of age
  • Routine vaccination against rubella is recommended for all children ≥12 mth; second dose should be routinely given at 4-6 yrs of age
  • Children ≤12 yr w/o previous immunization should be given at least 1 dose of MMR or MMRV
  • May be effective, theoretically, as post-exposure prophylaxis if given w/in 3 days of exposure
  • Single antigen is not routinely recommended

Prevention for Exposed Pregnant Women

  • Counseling regarding the risks & benefits of termination of pregnancy should be off ered to susceptible pregnant women exposed to rubella

Post-exposure Prophylaxis

  • Immunoglobulin may be given if termination of pregnancy is not an option based on maternal predilection
    • May reduce the risk of clinical infection but may not give an assurance of prevention of fetal infection
    • Dose of 0.55 mL/kg IM may be given
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Rachel Soon, 5 days ago

On 8 August, the first town hall held by the Ministry of Health (MOH) with members of the pharmacy profession took place in Putrajaya. Over 500 pharmacists from across the country and from different areas of practice—community and hospital, public and private, academy and industry—converged to fill the auditorium for the chance to engage in direct dialogue with MOH.

Stephen Padilla, 14 Aug 2019
Early administration of recombinant human B-type natriuretic peptide (rhBNP) can lower the incidence of reperfusion injury for patients with ST-elevation myocardial infarction (STEMI) who are receiving percutaneous coronary intervention (PCI) treatment, according to a China study.
11 Aug 2019
Intraoperative methylprednisolone does not appear to significantly prevent the incidence of death, cardiac arrest and other injuries in neonates undergoing cardiac surgery with cardiopulmonary bypass, according to a recent study.
3 days ago
Pulmonary function has potential predictive value for future increases in arterial stiffness and its progression, as reported in a recent study.